Eton (ETON) Director Charles Casamento Receives 10,000 RSUs

What Happened Charles J. Casamento, a director of Eton Pharmaceuticals (ETON), was granted 10,000 performance‑vested restricted stock units (RSUs) on July 31, 2026. The award is reported as a derivative grant (code A) at $0.00 per unit — no cash was paid. Each RSU represents the right to one share of common stock if and when the performance condition is satisfied.

Key Details

• Transaction date: July 31, 2026; Form filed Aug 4, 2026 (timely within SEC 2‑business‑day rule).
• Award: 10,000 RSUs, reported at $0.00 (derivative grant, code A).
• Vesting condition: Award vests in full only if the closing price of ETON common stock equals or exceeds $72.36 for one trading day at any time prior to July 31, 2029. If that market condition is not met by that date, the entire award is forfeited.
• Plan: Granted under the Issuer’s 2018 equity incentive plan.
• Number reported reflects the maximum and only shares issuable under the award (no threshold/target range).
• Shares beneficially owned after the transaction were not provided in the summary data.
• Filing note: The reporting person authorized a designated filer to submit this Form 4 on their behalf for an indefinite duration.

Context This is a performance‑based equity grant (not an immediate purchase or sale). Such grants are typically used for retention and to align director interests with stock performance; they have value only if the specified market price condition is met before the expiration date. For retail investors, a grant alone is neutral information — it does not indicate a buying or selling signal unless the insider subsequently buys or sells shares.